Evolutionary Action Score of TP53 Analysis in Pathologically High-Risk Human Papillomavirus-Negative Head and Neck Cancer From a Phase 2 Clinical Trial: NRG Oncology Radiation Therapy Oncology Group 0234

Authors

Chieko Michikawa
Pedro A Torres-Saavedra
Natalie L Silver
Paul M Harari
Merrill S Kies
David I Rosenthal
Quynh-Thu Le
Richard C Jordan
Dzifa Y Duose
Saradhi Mallampati
Sanchit Trivedi
Rajyalakshmi Luthra
Ignacio I Wistuba
Abdullah A Osman
Olivier Lichtarge
Robert L Foote
Upendra Parvathaneni
D Neil Hayes
Curtis R Pickering
Jeffrey N Myers

Publication Date

1-1-2022

Journal

Advances in Radiation Oncology

Abstract

PURPOSE: An evolutionary action scoring algorithm (EAp53) based on phylogenetic sequence variations stratifies patients with head and neck squamous cell carcinoma (HNSCC) bearing

METHODS AND MATERIALS: Eighty-one resection samples from patients treated surgically for stage III or IV human papillomavirus-negative HNSCC with high-risk pathologic features, who received either radiation therapy + cetuximab + cisplatin (cisplatin) or radiation therapy + cetuximab + docetaxel (docetaxel) as adjuvant treatment in a phase 2 study were subjected to

RESULTS: At a median follow-up of 9.8 years, there was a significant interaction between EAp53 group and treatment for overall survival (

CONCLUSIONS: The docetaxel arm was associated with better survival than the cisplatin arm for patients with wild-type or low-risk EAp53. These benefits appear to be largely driven by a reduction in DM.

Comments

Supplementary Materials

PMID: 36420184